LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

Search

Crinetics Pharmaceuticals Inc

Abrir

SetorSaúde

29.62 -0.1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.15

Máximo

30.69

Indicadores-chave

By Trading Economics

Rendimento

-16M

-97M

Vendas

361K

361K

EPS

-1.04

Margem de lucro

-26,807.202

Funcionários

437

EBITDA

-17M

-110M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+147.69% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-262M

2.9B

Abertura anterior

29.72

Fecho anterior

29.62

Sentimento de Notícias

By Acuity

50%

50%

174 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de mai. de 2025, 23:48 UTC

Ações em Alta

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 de mai. de 2025, 23:07 UTC

Principais Notícias

Fortescue Energy CEO to Resign in Executive Overhaul

22 de mai. de 2025, 23:03 UTC

Grandes Movimentos do Mercado

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 de mai. de 2025, 23:59 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2025, 23:23 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

22 de mai. de 2025, 23:23 UTC

Conversa de Mercado

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 de mai. de 2025, 23:12 UTC

Principais Notícias

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 de mai. de 2025, 21:54 UTC

Principais Notícias

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2025, 20:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 de mai. de 2025, 20:39 UTC

Ganhos

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 de mai. de 2025, 20:36 UTC

Principais Notícias

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 de mai. de 2025, 20:36 UTC

Principais Notícias
Ganhos

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 de mai. de 2025, 20:32 UTC

Principais Notícias
Ganhos

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 de mai. de 2025, 20:27 UTC

Principais Notícias

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 de mai. de 2025, 20:20 UTC

Principais Notícias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 de mai. de 2025, 20:17 UTC

Principais Notícias

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 de mai. de 2025, 20:16 UTC

Ganhos

Intchains Group 1Q Rev $18.2M >ICG

22 de mai. de 2025, 20:15 UTC

Principais Notícias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 de mai. de 2025, 20:08 UTC

Principais Notícias
Ganhos

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 de mai. de 2025, 20:05 UTC

Principais Notícias

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 de mai. de 2025, 20:04 UTC

Ganhos

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 de mai. de 2025, 20:04 UTC

Ganhos

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 de mai. de 2025, 20:01 UTC

Ganhos

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 de mai. de 2025, 20:01 UTC

Ganhos

Workday 1Q Net $68M >WDAY

22 de mai. de 2025, 20:01 UTC

Ganhos

Workday 1Q EPS 25c >WDAY

22 de mai. de 2025, 20:01 UTC

Ganhos

Workday 1Q Adj EPS $2.23 >WDAY

Comparação entre Pares

Variação de preço

Crinetics Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

147.69% parte superior

Previsão para 12 meses

Média 77.7 USD  147.69%

Máximo 100 USD

Mínimo 53 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

11

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

30.39 / 33.46Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

174 / 382 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.